ShangPharma, Qidong Biopharma ink agreement

Friday, September 25, 2015

ShangPharma has planned to establish a subsidiary in the Qidong Biopharma Industrial Zone as part of a multistage expansion project for its biologics service portfolio. In the first phase, ShangPharma and Qidong Biopharma Industrial Zone will invest $60 million to build a comprehensive and multifunctional preclinical research facility as well as a state-of-the-art biologics manufacturing facility.

[Read More]

ShangPharma appoints Arthur Taveras president and CSO

Monday, October 28, 2013

CRO ShangPharma has announced that Dr. Arthur Taveras will join the company as president and chief scientific officer. Taveras brings pharmaceutical leadership and technical experience in drug discovery, chemistry R&D and pharmaceutical development having worked as a pharmaceutical and biotech executive during his 24 year career.

[Read More]